The role of PCSK9 in inflammation, immunity, and autoimmune diseases

References

• Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282(25):18602–18612.
   PubMed Web of Science ®Google Scholar
• Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279(47):48865–48875.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272.
   PubMed Web of Science ®Google Scholar
• Kathiresan S. Myocardial Infarction Genetics C. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med. 2008;358(21):2299–2300.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156.
   PubMed Web of Science ®Google Scholar
• Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25(5):387–393.
   PubMed Web of Science ®Google Scholar
• Bergeron N, Phan BA, Ding Y, et al. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132(17):1648–1666.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Abifadel M, Prost S, et al. The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase Subtilisin/Kexin 9. Pharmacol Rev. 2017;69(1):33–52.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376(16):1527–1539.
   PubMed Web of Science ®Google Scholar
• Thompson RC, Allam AH, Lombardi GP, et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet. 2013;381:1211–1222.
   PubMed Web of Science ®Google Scholar
• Abdelfattah A, Allam AH, Wann S, et al. Atherosclerotic cardiovascular disease in Egyptian women: 1570 BCE-2011 CE. Int J Cardiol. 2012;167:570–574.
   PubMed Web of Science ®Google Scholar
• Murphy WA Jr., Nedden Dz D, Gostner P, et al. The iceman: discovery and imaging. Radiology. 2003;226(3):614–629.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145(1):33–43.
   PubMed Web of Science ®Google Scholar
• Frostegard J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11(1):117.
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity [see comments]. N Engl J Med. 1989;320(14):915–924.
   PubMed Web of Science ®Google Scholar
• Elinder LS, Dumitrescu A, Larsson P, et al. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol. 1997;17(10):2257–2263.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Wu R, Giscombe R, et al. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb. 1992;12(4):461–467.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Nilsson J, Haegerstrand A, et al. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci U S A. 1990;87(3):904–908.
   PubMed Web of Science ®Google Scholar
• Huang YH, Ronnelid J, Frostegard J. Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals. Arterioscler Thromb Vasc Biol. 1995;15(10):1577–1583.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Huang YH, Ronnelid J, et al. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol. 1997;17(5):963–968.
   PubMed Web of Science ®Google Scholar
• Liu A, Frostegard J. PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. J Intern Med. 2018;284:193–210.
   Web of Science ®Google Scholar
• Rahman M, Steuer J, Gillgren P, et al. Induction of dendritic cell-mediated activation of t cells from atherosclerotic plaques by human heat shock Protein 60. J Am Heart Assoc. 2017;6(11). DOI:https://doi.org/10.1161/JAHA.117.006778
   Google Scholar
• Liu A, Ming JY, Fiskesund R, et al. Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins. Arterioscler Thromb Vasc Biol. 2015;35(1):197–205.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Zhang Y, Sun J, et al. Oxidized Low-Density Lipoprotein (OxLDL)-treated dendritic cells promote activation of T cells in human atherosclerotic plaque and blood, which is repressed by statins: microRNA let-7c is integral to the effect. J Am Heart Assoc. 2016;5(9). DOI:https://doi.org/10.1161/JAHA.116.003976
   Google Scholar
• Rahman M, Steuer J, Gillgren P, et al. Malondialdehyde conjugated with albumin induces pro-inflammatory activation of T cells isolated from human atherosclerotic plaques both directly and via dendritic cell-mediated mechanism. JACC Basic Transl Sci. 2019;4(4):480–494.
   PubMedGoogle Scholar
• Frostegard J, Svenungsson E, Wu R, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 2005;52(1):192–200.
   PubMedGoogle Scholar
• Frostegard J, Wu R, Lemne C, et al. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci (Lond). 2003;105(5):615–620.
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104(16):1887–1893.
   PubMed Web of Science ®Google Scholar
• Iribarren C, Jacobs DR Jr., Sidney S, et al. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect. 1998;121(2):335–347.
   PubMed Web of Science ®Google Scholar
• Feingold KR, Grunfeld C. Lipids: a key player in the battle between the host and microorganisms. J Lipid Res. 2012;53(12):2487–2489.
   PubMed Web of Science ®Google Scholar
• Wurfel MM, Kunitake ST, Lichenstein H, et al. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994;180(3):1025–1035.
   PubMed Web of Science ®Google Scholar
• Kaysen GA, Ye X, Raimann JG, et al. Lipid levels are inversely associated with infectious and all-cause mortality: international MONDO study results. J Lipid Res. 2018;59(8):1519–1528.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Stern J, Bouzid D, et al. Relationship between lipoprotein concentrations and short-term and 1-year mortality in intensive care unit septic patients: results from the HIGHSEPS study. Ann Intensive Care. 2021;11(1):11.
   PubMed Web of Science ®Google Scholar
• Sijbrands EJ, Westendorp RG, Defesche JC, et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. Bmj. 2001;322(7293):1019–1023.
   PubMedGoogle Scholar
• Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010;51(6):1486–1495.
   PubMed Web of Science ®Google Scholar
• Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49(2):394–398.
   PubMed Web of Science ®Google Scholar
• Camps J, Castane H, Rodriguez-Tomas E, et al. On the role of paraoxonase-1 and chemokine ligand 2 (C-C motif) in metabolic alterations linked to inflammation and disease. A 2021 update. Biomolecules. 2021;11(7):971.
   PubMed Web of Science ®Google Scholar
• Leander K, Malarstig A, Van’t Hooft FM, et al. Circulating proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circulation. 2016;133(13):1230–1239.
   PubMed Web of Science ®Google Scholar
• Xie W, Liu J, Wang W, et al. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study. Int J Cardiol. 2016;215:293–298.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Bradwin G, et al. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J. 2016;37(6):554–560.
   PubMed Web of Science ®Google Scholar
• Zhu YM, Anderson TJ, Sikdar K, et al. Association of proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) with cardiovascular risk in primary prevention. Arterioscler Thromb Vasc Biol. 2015;35(10):2254–2259.
   PubMed Web of Science ®Google Scholar
• Di Minno A, Orsini RC, Chiesa M, et al. Treatment with PCSK9 inhibitors in patients with familial hypercholesterolemia lowers plasma levels of platelet-activating factor and its precursors: a combined metabolomic and lipidomic approach. Biomedicines. 2021;9(8):1073.
   PubMed Web of Science ®Google Scholar
• Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220(2):381–386.
   PubMed Web of Science ®Google Scholar
• Ding Z, Liu S, Wang X, et al. PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc Res. 2018;114(8):1145–1153.
   PubMed Web of Science ®Google Scholar
• Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8(1):2267.
   PubMedGoogle Scholar
• Giunzioni I, Tavori H, Covarrubias R, et al. Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol. 2016;238(1):52–62.
   PubMed Web of Science ®Google Scholar
• Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6(2):131–138.
   PubMedGoogle Scholar
• Millonig G, Niederegger H, Rabl W, et al. Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol. 2001;21(4):503–508.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Lochno M, Traeg F, et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis. 2004;176(1):101–110.
   PubMed Web of Science ®Google Scholar
• Liu P, Yu YR, Spencer JA, et al. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol. 2008;28(2):243–250.
   PubMed Web of Science ®Google Scholar
• Bobryshev YV, Watanabe T. Ultrastructural evidence for association of vascular dendritic cells with T-lymphocytes and with B-cells in human atherosclerosis. J Submicrosc Cytol Pathol. 1997;29(2):209–221.
   PubMedGoogle Scholar
• Frostegard J, Kjellman B, Gidlund M, et al. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis. 1996;121(1):93–103.
   PubMed Web of Science ®Google Scholar
• Zhou X, Nicoletti A, Elhage R, et al. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102(24):2919–2922.
   PubMed Web of Science ®Google Scholar
• Gojova A, Brun V, Esposito B, et al. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood. 2003;102(12):4052–4058.
   PubMed Web of Science ®Google Scholar
• Kolbus D, Ljungcrantz I, Andersson L, et al. Association between CD8+ T-cell subsets and cardiovascular disease. J Intern Med. 2013;274(1):41–51.
   PubMed Web of Science ®Google Scholar
• Liu A, Rahman M, Hafstrom I, et al. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus. Lupus. 2020;29(8):825–835.
   Web of Science ®Google Scholar
• Kim YU, Kee P, Danila D, et al. A critical role of PCSK9 in mediating IL-17-producing T cell responses in hyperlipidemia. Immune Netw. 2019;19(6):e41.
   PubMed Web of Science ®Google Scholar
• Liu X, Bao X, Hu M, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588(7839):693–698.
   PubMed Web of Science ®Google Scholar
• Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62(11):1071–1077.
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–415.
   PubMed Web of Science ®Google Scholar
• Anania C, Gustafsson T, Hua X, et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther. 2010;12(6):R214.
   PubMed Web of Science ®Google Scholar
• Su J, Hua X, Concha H, et al. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford). 2008;47(8):1144–1150.
   PubMed Web of Science ®Google Scholar
• Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus. 1997;6(6):533–539.
   PubMed Web of Science ®Google Scholar
• Cederholm A, Svenungsson E, Jensen-Urstad K, et al. Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol. 2005;25(1):198–203.
   PubMed Web of Science ®Google Scholar
• Fang C, Luo T, Lin L. Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus. Ann Transl Med. 2018;6(23):452.
   PubMed Web of Science ®Google Scholar
• Ministrini S, Carbone F. PCSK9 and inflammation. Maybe a role in autoimmune diseases? Focus on rheumatoid arthritis and systemic lupus erythematosus. Curr Med Chem. 2021;28. DOI:https://doi.org/10.2174/0929867328666210810150940
   Google Scholar
• Sanchez-Perez H, Quevedo-Abeledo JC, Tejera-Segura B, et al. Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975904.
   PubMed Web of Science ®Google Scholar
• Ochoa E, Iriondo M, Manzano C, et al. LDLR and PCSK9 are associated with the presence of antiphospholipid antibodies and the development of thrombosis in aPLA carriers. PLoS One. 2016;11(1):e0146990.
   PubMed Web of Science ®Google Scholar
• Melendez QM, Wooten CJ, Krishnaji ST, et al. Identification of novel proteins interacting with proprotein convertase Subtilisin/Kexin 9. Int J Biomed Invest. 2020;3(1). DOI:https://doi.org/10.31531/2581-4745.1000123
   Google Scholar
• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337(3):141–147.
   PubMed Web of Science ®Google Scholar
• Wijbrandts CA, Tak PP. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc. 2017;92(7):1129–1143.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Nagy G, Tak PP. Early start and stop of biologics: has the time come? BMC Med. 2014;12:25.
   PubMed Web of Science ®Google Scholar
• Frostegard J. Cardiovascular co-morbidity in patients with rheumatic diseases. Arthritis Res Ther. 2011;13(3):225.
   PubMed Web of Science ®Google Scholar
• Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014;53(12):2143–2154.
   PubMed Web of Science ®Google Scholar
• Karpouzas GA, Ormseth SR, Hernandez E, et al. Biologics may prevent cardiovascular events in rheumatoid arthritis by inhibiting coronary plaque formation and stabilizing high-risk lesions. Arthritis Rheumatol. 2020;72:1467–1475.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Ahmed S, Hafstrom I, et al. Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-alpha: potential underlying mechanisms. Arthritis Res Ther. 2021;23(1):32.
   PubMed Web of Science ®Google Scholar
• Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother. 2017;92:615–633.
   PubMed Web of Science ®Google Scholar
• Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol. 2016;12(8):472–485.
   PubMed Web of Science ®Google Scholar
• Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992;90(3):772–779.
   PubMed Web of Science ®Google Scholar
• Shahrara S, Proudfoot AE, Park CC, et al. Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol. 2008;180(5):3447–3456.
   PubMed Web of Science ®Google Scholar
• Winyard PG, Tatzber F, Esterbauer H, et al. Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis. 1993;52(9):677–680.
   PubMed Web of Science ®Google Scholar
• Nowak B, Madej M, Luczak A, et al. Disease activity, oxidized-LDL fraction and anti-oxidized LDL antibodies influence cardiovascular risk in rheumatoid arthritis. Adv Clin Exp Med. 2016;25(1):43–50.
   PubMed Web of Science ®Google Scholar
• Scheinecker C, Goschl L, Bonelli M. Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun. 2020;110:102376.
   PubMed Web of Science ®Google Scholar
• Krahel JA, Baran A, Kaminski TW, et al. Methotrexate decreases the level of PCSK9-A novel indicator of the risk of proatherogenic lipid profile in psoriasis. The preliminary data. J Clin Med. 2020;9(4):910.
   Web of Science ®Google Scholar